Deutsche Bank AG Makes New $357,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Deutsche Bank AG acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 25,877 shares of the biotechnology company's stock, valued at approximately $357,000. Deutsche Bank AG owned approximately 0.06% of Capricor Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $742,000. Bank of America Corp DE boosted its position in Capricor Therapeutics by 938.9% during the fourth quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company's stock worth $2,353,000 after purchasing an additional 154,127 shares in the last quarter. Freestone Grove Partners LP acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $316,000. Northern Trust Corp increased its position in shares of Capricor Therapeutics by 43.3% in the fourth quarter. Northern Trust Corp now owns 384,157 shares of the biotechnology company's stock valued at $5,301,000 after buying an additional 116,086 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Trading Up 10.7%

CAPR stock traded up $1.19 during midday trading on Wednesday, reaching $12.34. The stock had a trading volume of 2,616,793 shares, compared to its average volume of 1,761,529. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The company's fifty day simple moving average is $10.15 and its 200 day simple moving average is $13.03. The company has a market cap of $563.65 million, a price-to-earnings ratio of -11.64 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter last year, the company earned ($0.31) earnings per share. Sell-side analysts predict that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Analyst Ratings Changes

CAPR has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Roth Capital assumed coverage on shares of Capricor Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $31.00 price target for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $35.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.